urea has been researched along with narlaprevir in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (90.91) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Arasappan, A; Bennett, F; Chase, R; Feld, B; Guo, Z; Hart, A; Madison, V; Malcolm, B; Njoroge, FG; Pichardo, J; Prongay, A; Ralston, R; Skelton, A; Tong, X; Xia, E; Zhang, R | 1 |
| Clement, RP; Cunliffe, JM; Dreyer, DP; Hayes, RN; Shen, JX | 1 |
| Bergmann, JF; de Bruijne, J; de Knegt, RJ; Hughes, EA; Janssen, HL; Li, J; Molenkamp, R; Reesink, HW; Schinkel, J; Tong, X; Treitel, MA; van Lier, JJ; van Vliet, AA; Weegink, CJ | 1 |
| Clement, RP; Cunliffe, JM; Dreyer, DP; Hayes, RN; Shen, JX; Wei, X | 1 |
| Arjomand, A; Chowdhury, SK; Gao, L; Hesk, D; Kasserra, C; Li, J; Song, Q | 1 |
| Hou, T; Li, Y; Mao, X; Yu, H; Zhang, L; Zhu, J | 1 |
| Boonstra, A; de Bruijne, J; de Knegt, RJ; Hotho, DM; Janssen, HL; Reesink, HW; Spaan, M; Treitel, MA | 1 |
| Bergmann, JF; de Bruijne, J; de Knegt, RJ; Hughes, E; Janssen, HL; Molenkamp, R; Rebers, SP; Reesink, HW; Schinkel, J; Thomas, XV; Treitel, MA; Weegink, CJ | 1 |
| Chen, BZ; Geng, L; Ji, M; Wang, H | 1 |
| Batskikh, SN; Burnevich, EZ; Chulanov, VP; Gusev, DA; Kizlo, SN; Klimova, EA; Krasavina, EN; Mamonova, NA; Samsonov, MY; Tarkhova, EP; Yushchuk, ND; Znoyko, OO | 1 |
| Bai, Y; Feng, Y; Fu, L; Gao, GF; Liao, H; Qi, J; Shi, Y; Song, H; Tan, W; Ye, F | 1 |
4 trial(s) available for urea and narlaprevir
| Article | Year |
|---|---|
Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients.
Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Dipeptides; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Inpatients; Interferon alpha-2; Interferon-alpha; Leucine; Male; Middle Aged; Outpatients; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ritonavir; RNA, Viral; Sulfones; Urea; Young Adult | 2010 |
Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long-term follow-up.
Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leucine; Male; Middle Aged; Placebos; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Sulfones; Treatment Outcome; Urea; Viral Load | 2013 |
Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor.
Topics: Adult; Antiviral Agents; Cyclopropanes; Dipeptides; Drug Therapy, Combination; Evolution, Molecular; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leucine; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Sulfones; Urea; Viral Load; Viral Nonstructural Proteins | 2013 |
[Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C].
Topics: Adult; Antiviral Agents; Carbamates; Cyclopropanes; Dipeptides; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Leucine; Middle Aged; Proline; Pyrrolidines; Ritonavir; Russia; Sulfones; Treatment Outcome; Urea; Valine | 2019 |
7 other study(ies) available for urea and narlaprevir
| Article | Year |
|---|---|
Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
Topics: Antiviral Agents; Cyclopropanes; Dipeptides; Drug Discovery; Drug Evaluation, Preclinical; Drug Resistance, Viral; Genotype; Hepacivirus; Humans; In Vitro Techniques; Interferon alpha-2; Interferon-alpha; Kinetics; Leucine; Mutation; Proline; Protease Inhibitors; Recombinant Proteins; Replicon; Sulfones; Urea; Viral Nonstructural Proteins | 2010 |
Using temperature to optimize resolution and reduce analysis times for bioanalytical diastereomer LC-MS/MS separations.
Topics: Chemistry Techniques, Analytical; Chemistry, Pharmaceutical; Chromatography; Chromatography, High Pressure Liquid; Chromatography, Liquid; Cyclopropanes; Dipeptides; Humans; Leucine; Proline; Reproducibility of Results; Stereoisomerism; Sulfones; Tandem Mass Spectrometry; Temperature; Time Factors; Urea | 2011 |
Implementation of high-temperature superficially porous technologies for rapid LC-MS/MS diastereomer bioanalysis.
Topics: Blood Chemical Analysis; Chromatography, High Pressure Liquid; Cyclopropanes; Dipeptides; Humans; Leucine; Lysophosphatidylcholines; Phosphatidylcholines; Proline; Stereoisomerism; Sulfones; Tandem Mass Spectrometry; Technology, Pharmaceutical; Temperature; Urea | 2011 |
Precision and accuracy in the quantitative analysis of biological samples by accelerator mass spectrometry: application in microdose absolute bioavailability studies.
Topics: Administration, Oral; Adult; Antiviral Agents; Calibration; Chromatography, Liquid; Cyclopropanes; Dipeptides; Humans; Injections, Intravenous; Leucine; Male; Middle Aged; Proline; Reproducibility of Results; Sensitivity and Specificity; Sulfones; Tandem Mass Spectrometry; Urea; Young Adult | 2011 |
Insight into the structural requirements of narlaprevir-type inhibitors of NS3/NS4A protease based on HQSAR and molecular field analyses.
Topics: Antiviral Agents; Carrier Proteins; Cyclopropanes; Dipeptides; Drug Design; Hepacivirus; Hepatitis C; Humans; Intracellular Signaling Peptides and Proteins; Leucine; Models, Molecular; Proline; Quantitative Structure-Activity Relationship; Sulfones; Urea; Viral Nonstructural Proteins | 2012 |
Computational study on the molecular mechanisms of drug resistance of Narlaprevir due to V36M, R155K, V36M+R155K, T54A, and A156T mutations of HCV NS3/4A protease.
Topics: Antiviral Agents; Cyclopropanes; Dipeptides; Drug Resistance, Viral; Genes, Viral; Hepacivirus; Leucine; Molecular Dynamics Simulation; Mutation; Proline; Sulfones; Urea; Viral Nonstructural Proteins | 2014 |
Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir.
Topics: Coronavirus 3C Proteases; COVID-19; COVID-19 Drug Treatment; Cyclopropanes; Cysteine Proteinase Inhibitors; Hepacivirus; Humans; Leucine; Proline; SARS-CoV-2; Sulfones; Urea | 2021 |